Brought to you by the Center for Professional Development with a special thank you to the content writers and presenters, Theresa A. Kuracina, MS, RD, CDE, LN, and Andrew Narva, MD, FACP, at the National Kidney Disease Education Program (NKDEP)
In this module we will discuss the role of hypertension, diabetes, albuminuria and cardiovascular disease (CVD) in CKD progression. Our case study will follow a patient, Frank, as he approaches kidney failure. You will see how certain anti-hypertensive medications impact Frank's serum potassium and urine albumin levels. Diabetes control and appropriate treatment of hypoglycemia, risk factors and interventions for lowering urine albumin levels, and traditional and non-traditional risk factors for CVD will be discussed.
CPE Level: 2
Suggested Learning Need Codes: 5340, 5000, 5190, 5160
- Use and interpret biochemical and patient data for assessment of hypertension and CKD.
- Identify commonly prescribed classes of anti-hypertensive medications that may affect serum potassium levels in CKD.
- Associate spontaneous improvement in diabetes mellitus (DM) control with possible CKD progression.
- Modify recommendations for appropriate treatment of hypoglycemia in DM and CKD.
- Identify at least two nontraditional risk factors for cardiovascular disease in CKD.
This e-learning self-study includes web links to the National Cholesterol Education Program Final Report, the USDA Nutrient Database, the education handout Eating Right for Kidney Health and additional Online Learning opportunities.
The course includes PDF files of the speaker presentations and handouts as well as a downloadable CPE certificate.
The Certificate of Training program consists of five separate modules that build on each other. To receive the certificate associated with this training, all five modules and related tests must first be completed and a subsequent final post test exam in Module 5 must be passed with a minimum of an 80% in order to receive the Certificate of Training. The Certificate of Training can then be downloaded and printed from the site.
Revised modules now reflect the following recommendations for CKD patients:
- Sodium intake of < 2,300 mg rather than < 1,500 mg per day (IOM, 2013)
- Blood pressure target of < 140/90 mm Hg rather than < 130/80 mm Hg (JNC 8, 2014)
- Initial antihypertensive treatment with an ACEi or ARB (JNC 8, 2014).
Immediately following purchase, you will receive an access email for the module. This email contains a link which will remain active for 30 days once the link has been activated by the user.
This product is approved for individual use only. Only the registered participant is eligible for continuing professional education units.
Please note: Upon completion of your order, a link to access your purchase will be sent to the email address you have on file with the Academy. Please be sure your email address is accurate before submitting your order. If you have difficulty with your purchase, please contact email@example.com. Thank you.